Prevalence of Thrombocytopenia in COVID-19 Isolated Patients

Hassan, Hossam Hassan Saied; Ahmed, Yousef Khalil; Nasser, Youssef Abdallah Yousef; Aboghabsha, Mohammad Assayed

doi:10.21608/ijma.2023.185653.1592

	Prevalence of Thrombocytopenia in COVID-19 Isolated Patients
International Journal of Medical Arts
Article 5, Volume 4, Issue 12, December 2022, Page 2885-2890 PDF (973.55 K)
Document Type: Original Article
DOI: 10.21608/ijma.2023.185653.1592
View on SCiNiTO
Authors
Hossam Hassan Saied Hassan ¹; Yousef Khalil Ahmed¹; Youssef Abdallah Yousef Nasser¹; Mohammad Assayed Aboghabsha²
¹Department of Internal Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
²Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Abstract
Background: Sever Acute Respiratory Syndrome Coronavirus [SARS-COV-2], a new highly transmittable coronavirus, with many variants recently appearing and spreading rapidly around the world. Aim of the Work: To find out the prevalence of thrombocytopenia in COVID-19 patients, and the association between the severity of thrombocytopenia and severity of the disease in COVID-19 patients. Patients and Methods: The current prospective study will include 300 patients with COVID-19 infection sector in Al Hussein University Hospital, Al-Azhar University, the inclusion Criteria included: Age between 18-60 years, positive nasopharyngeal swab PCR for COVID-19 RNA and isolated new-onset thrombocyte-penia, while the exclusion criteria included: history of liver cirrhosis or HCV, history of bone marrow disease or ITP, history of autoimmune disease or immunosuppressive therapy and previous treatment with platelet transfusion, danazol , or thrombopoietin receptor agonists, the eligible patients will be divided into 2 groups: group I: patients without thrombocytopenia, while group II: patients with thrombocytopenia. Results: The studied patients who developed thrombocytopenia were 95/300 patients [31.7%], with variable degrees of thrombocyte-penia, half of those patients with moderate thrombocytopenia died from COVID, while 5/15 patients [33.3%] of those who developed severe thrombocytopenia, died from COVID, with statistically significant difference, P-value= 0.01. Conclusion: Thrombocytopenia may be considered as a risk factor for mortality among patients who developed COVID infection.
Keywords
COVID; Thrombocytopenia; Platelet


Statistics Article View: 179 PDF Download: 76